Peripheral Neuropathy Market at a CAGR of 9.1% to Estimated $ 7,250 Million Growth by 2030
The Peripheral Neuropathy Market is expected to reach USD 7,250 Million by 2030 at 9.1% CAGR during the forecast period 2022-2030.
Peripheral neuropathy is a result of damage to the nerves outside of the brain, and spinal cord (peripheral nerves) causes numbness and pain, also weakness in your hands and feet. It can also affect other areas of your body. As peripheral neuropathy If left untreated, leads to serious effects, such as burning pain or paralysis; hence, companies are investing in peripheral neuropathy market to find the new drugs and treatment methods.
Technological advancements and product launches by key players in the peripheral neuropathy market are likely to act as a promising factor for the growth of the market in the near future.
Peripheral Neuropathy Market Drivers
Peripheral Neuropathy Market Segmentation
Peripheral Neuropathy Market Key Players
|Market Size||USD 7,250 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Treatment and End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott Laboratories (US), Bristol Myers Squibb (US), Novartis AG (UK), Eli Lilly and Company (US), Pfizer Inc (US), GlaxoSmithKline plc (UK), Merck and Co. Inc. (US), Cipla Limited (India), Lupin Limited (India), Reddy's Laboratories (India), Hoffmann-La Roche Ltd. (UK), RxFunction, Inc. (US)|
|Key Market Opportunities||Technological advancements and product launches by key players|
|Key Market Drivers||
The valuation of the peripheral neuropathy market is estimated to reach USD 7,250 Million by 2030.
The peripheral neuropathy market is projected to grow at approximately 9.1% CAGR during the forecast period (2022-2030).
Growing prevalence of diabetes.
North America holds the largest share in the peripheral neuropathy market, followed by Europe and the Asia Pacific, respectively.
Bristol Myers Squibb (US), Abbott Laboratories (US), Novartis AG (UK), Pfizer Inc (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Cipla Limited (India), Merck and Co. Inc. (US), Lupin Limited (India), Hoffmann-La Roche Ltd. (UK), Reddy's Laboratories (India), and RxFunction, Inc. (US), are some of the major players operating in the peripheral neuropathy market.